Claims for Patent: 5,693,532

Summary for Patent: 5,693,532

Title:	Respiratory syncytial virus ribozymes
Abstract:	An enzymatic RNA molecule which cleaves respiratory syncytial virus (RSV) genomic and RSV encoded RNA.
Inventor(s):	McSwiggen; James (Boulder, CO), Draper; Kenneth (Boulder, CO), Pavco; Pam (Layfayette, CO), Woolf; Tod (Watertown, MA)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/334,847
Patent Claims:	1. An enzymatic RNA molecule which specitically cleaves genomic RNA of RSV or mRNA encoded by RSV in a region selected from the group consisting of 1C, 1B and N. 2. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule comprises at least one sugar modification. 3. The enzymatic RNA molecule of claim 1, wherein said RNA molecule is in a hammerhead motif. 4. The hammerhead enzymatic RNA molecule of claim 3, wherein said hammerhead RNA molecule comprises sequences complementary to any of sequences defined as Seq ID Nos. 7-133, 261-351, and 443-666. 5. The enzymatic RNA molecule of claim 1, wherein said RNA molecule is in a hairpin, hepatitis Delta virus, group 1 intron, Neurospora VS RNA or RNaseP RNA motif. 6. The enzymatic RNA molecule of claim 5, wherein said enzymatic RNA molecule is in a hairpin motif and wherein said hairpin motif comprises sequences complementary to any of sequences defined as Seq ID Nos. 894-896 and 903-908. 7. The enzymatic RNA molecule of claim 1, wherein said ribozyme comprises between 12 and 100 bases complementary to the RNA of said region. 8. The enzymatic RNA of claim 7, wherein said ribozyme comprises between 14 and 24 bases complementary to the RNA of said region. 9. The enzymatic RNA molecule of claim 1 wherein said enzymatic RNA molecule comprises any sequence selected from the group consisting of SEQ ID Nos. 134-260, 352-442, 667-890, 894-896, and 897-902. 10. A mammalian cell including an enzymatic RNA molecule of claim 1 in vitro. 11. The cell of claim 10, wherein said cell is a human cell. 12. An expression vector comprising nucleic acid encoding the enzymatic RNA molecule of claim 1, in a manner which allows expression and/or delivery of that enzymatic RNA molecule within a mammalian cell in vitro. 13. A mammalian cell in vitro including an expression vector of claim 12. 14. The cell of claim 13, wherein said cell is a human cell.

Details for Patent 5,693,532

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26